Weight Loss Drugs May Pose Risk of Blindness, FDA Warns
Translated & summarized from Srugim by baba
The U.S. FDA is mandating new warnings for popular GLP-1 weight loss drugs like Ozempic and Wegovy, citing a rare risk of optic nerve damage that could lead to irreversible blindness. While clinical trials suggest a slight increase in vision impairment cases among users, experts stress the condition remains extremely rare. Patients experiencing sudden vision changes are advised to seek immediate medical help, but doctors suggest not to halt treatment without consultation due to the drugs' significant health benefits.
The story in 6 lines · by baba
- FDA requires warnings on GLP-1 drugs like Ozempic for rare blindness risk.
- Optic nerve damage can cause irreversible vision loss in rare cases.
- Clinical trials show a slight increase in vision impairment among users.
- Experts emphasize the condition's extreme rarity, affecting less than 1 in 10,000.
- Patients with sudden vision issues should seek immediate medical attention.
- Doctors advise against stopping treatment without consultation.
The U.S. Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 family weight loss drugs to add warnings about a potential risk of optic nerve damage, which in rare cases could lead to irreversible blindness. The popular medications, including Wegovy, Ozempic, and Mounjaro, are widely used for treating obesity and diabetes.
This rare side effect, though potentially causing significant vision impairment, has emerged following a review of clinical trials involving over 134,000 participants. The data indicated approximately 6.5 cases of vision impairment among drug users compared to nearly four cases among non-users, though the basis for these rates was not specified. An eye care specialist described the risk as extremely low, affecting less than 1 in 10,000 individuals, but stressed the need for caution with any serious potential side effect.
The damage affects the optic nerve, which transmits visual information to the brain, and can manifest as a loss of visual field, akin to a small stroke in the nerve. The specialist noted that some risk factors for optic nerve damage, such as diabetes, smoking, high blood pressure, and sleep apnea, are common among individuals with obesity.
While acknowledging a nearly 50% increase in risk among users, the expert emphasized the rarity of the condition. He advised that patients experiencing sudden blurred vision, blind spots, or a sharp decline in sight should seek immediate medical attention. However, he cautioned against a blanket discontinuation of treatment, suggesting that doctors can assess individual risk and discuss whether to continue or stop the medication. He also pointed out the significant health benefits of GLP-1 drugs and that other medical treatments also carry potential side effects.
An editorial note stated the article was based solely on the provided transcript and did not include independent verification of the FDA announcement, its application to all mentioned drugs, or the numerical data.
